NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Ultima Genomics

Ultima Genomics

Private
Newark, CaliforniaHealthcare & Life Scienceshttps://www.ultimagenomics.com/

Last Round

Early Funding

May 31, 2022

Total Funding Raised

$604.45M

Company Overview

Ultima Genomics is a biotechnology company that develops and manufactures high-throughput, low-cost genome sequencing platforms.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Biotech Equipment, Precision Medicine

Business Model

B2B

Customer Profile

Usage-Based SaaS, Hardware Sales

AI Layer

Infrastructure

Keywords

DNA sequencingnext-generation sequencingNGShigh-throughput sequencinggenomic dataminimal residual diseaseMRDwhole genome sequencingWGSsingle-cell analysismulti-omicslow-cost sequencingbioaisequencing platformgenomics at scale100 dollar genome

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ultima Genomics Comparables

Compare Ultima Genomics with similar companies based on industry and business-model similarity.

Ultima Genomics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Element Biosciences
88%
MGI
78%
GeneMind Biosciences Co., Ltd.
77%

Ultima Genomics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingMay 31, 2022
GrantApr 1, 2021

Secondary Market Activity

Bids, offers, and trades by month

Data table
OperationDatePriceSizeShare ClassStructure
OFFER

Key People

Founding team and executive leadership

Gilad Almogy

Founder And CEO

Founding Team

David Peoples

Chief Financial Officer

Executive Team

Ultima Genomics Investors

Notable investors and investment history

Ultima Genomics investors
InvestorRounds
Andreessen HorowitzEarly Funding
Khosla VenturesEarly Funding, Seed
NIH RADxGrant
Playground GlobalEarly Funding
Founders FundEarly Funding
D1 Capital PartnersEarly Funding
aMoonEarly Funding

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 26, 2026

    Launched the UG200 Series, a next-generation sequencing platform.

  • Feb 25, 2026

    Presented technologies at the AGBT Conference on February 25, 2026.

Ultima Genomics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Ultima Genomics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Ultima Genomics's valuation, stock price, and market status.

Firmographic Details

HeadquartersNewark, California
Employee Range305
Year Founded2016
Last FundingMay 31, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.